BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 31138318)

  • 21. MicroRNA-765 targets MTUS1 to promote the progression of osteosarcoma via mediating ERK/EMT pathway.
    Lv DB; Zhang JY; Gao K; Yu ZH; Sheng WC; Yang G; Gao YZ
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4618-4628. PubMed ID: 31210288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein kinase Cα mediates erlotinib resistance in lung cancer cells.
    Abera MB; Kazanietz MG
    Mol Pharmacol; 2015 May; 87(5):832-41. PubMed ID: 25724832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. microRNA-377-3p inhibits osteosarcoma progression by targeting CUL1 and regulating Wnt/β-catenin signaling pathway.
    Liang K; Liao L; Liu Q; Ouyang Q; Jia L; Wu G
    Clin Transl Oncol; 2021 Nov; 23(11):2350-2357. PubMed ID: 34133001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.
    Adam L; Zhong M; Choi W; Qi W; Nicoloso M; Arora A; Calin G; Wang H; Siefker-Radtke A; McConkey D; Bar-Eli M; Dinney C
    Clin Cancer Res; 2009 Aug; 15(16):5060-72. PubMed ID: 19671845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
    Han J; Zhao F; Zhang J; Zhu H; Ma H; Li X; Peng L; Sun J; Chen Z
    Int J Oncol; 2016 May; 48(5):1855-67. PubMed ID: 26936292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells.
    Luo Y; Liu W; Tang P; Jiang D; Gu C; Huang Y; Gong F; Rong Y; Qian D; Chen J; Zhou Z; Zhao S; Wang J; Xu T; Wei Y; Yin G; Fan J; Cai W
    J Exp Clin Cancer Res; 2019 Dec; 38(1):488. PubMed ID: 31829261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex-determining region Y-box protein 3 induces epithelial-mesenchymal transition in osteosarcoma cells via transcriptional activation of Snail1.
    Qiu M; Chen D; Shen C; Shen J; Zhao H; He Y
    J Exp Clin Cancer Res; 2017 Mar; 36(1):46. PubMed ID: 28335789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.
    Wang X; Yin H; Zhang H; Hu J; Lu H; Li C; Cao M; Yan S; Cai L
    Cell Death Dis; 2018 Apr; 9(4):418. PubMed ID: 29549343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma.
    Vaquero J; Lobe C; Tahraoui S; Clapéron A; Mergey M; Merabtene F; Wendum D; Coulouarn C; Housset C; Desbois-Mouthon C; Praz F; Fouassier L
    Clin Cancer Res; 2018 Sep; 24(17):4282-4296. PubMed ID: 29716918
    [No Abstract]   [Full Text] [Related]  

  • 31. Long Noncoding RNA SNHG7 Promotes the Tumor Growth and Epithelial-to-Mesenchymal Transition via Regulation of miR-34a Signals in Osteosarcoma.
    Deng Y; Zhao F; Zhang Z; Sun F; Wang M
    Cancer Biother Radiopharm; 2018 Nov; 33(9):365-372. PubMed ID: 29989838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.
    Haque I; Kawsar HI; Motes H; Sharma M; Banerjee S; Banerjee SK; Godwin AK; Huang CH
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
    Sesumi Y; Suda K; Mizuuchi H; Kobayashi Y; Sato K; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2017 Feb; 104():85-90. PubMed ID: 28213007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-210 is increased and it is required for dedifferentiation of osteosarcoma cell line.
    Zhang H; Mai Q; Chen J
    Cell Biol Int; 2017 Mar; 41(3):267-275. PubMed ID: 28032372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long Noncoding RNA GAS5 Suppresses Cell Growth and Epithelial-Mesenchymal Transition in Osteosarcoma by Regulating the miR-221/ARHI Pathway.
    Ye K; Wang S; Zhang H; Han H; Ma B; Nan W
    J Cell Biochem; 2017 Dec; 118(12):4772-4781. PubMed ID: 28519068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.
    Iderzorig T; Kellen J; Osude C; Singh S; Woodman JA; Garcia C; Puri N
    Biochem Biophys Res Commun; 2018 Feb; 496(2):770-777. PubMed ID: 29337056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics.
    Dang H; Ding W; Emerson D; Rountree CB
    BMC Cancer; 2011 Sep; 11():396. PubMed ID: 21929801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.
    Liao J; Lin J; Lin D; Zou C; Kurata J; Lin R; He Z; Su Y
    Sci Rep; 2017 Apr; 7(1):781. PubMed ID: 28396596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/
    Zhang H; Chen F; He Y; Yi L; Ge C; Shi X; Tang C; Wang D; Wu Y; Nian W
    Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28507201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.